Abstract
Parthenogenetic embryonic stem (pES) cells are pluripotent stem cells derived from artificially activated oocytes without embryo destruction, thus eliciting less ethic concerns, and have been demonstrated promising for autologous stem cell therapy. However, pES cells could carry inappropriate imprinting such as relatively high expression of H19, a paternal imprinted gene, and may negatively influence their lineage differentiation. We show that knockdown of H19 by shRNA in mouse pES cells does not alter self-renewal and expression of genes associated with pluripotency. We find that down-regulation of H19 promotes differentiation of pES cells to epidermis. In addition, H19 depletion also facilitates differentiation of pES cells to cardiomyocytes and strong heart-like beating. Our data support the notion that reduction of H19 improves pES cell differentiation in the lineages of ectoderm and mesoderm, and provide further evidence suggesting that defective imprinting can be manipulated to allow potential application of pES cells for stem cell therapy.
Keywords: Differentiation, H19, parthenogenetic stem cells.
Current Molecular Medicine
Title:Knockdown of H19 Enhances Differentiation Capacity to Epidermis of Parthenogenetic Embryonic Stem Cells
Volume: 14 Issue: 6
Author(s): Y. Yin, H. Wang, K. Liu, F. Wang, X. Ye, M. Liu, R. Xiang, N. Liu and L. Liu
Affiliation:
Keywords: Differentiation, H19, parthenogenetic stem cells.
Abstract: Parthenogenetic embryonic stem (pES) cells are pluripotent stem cells derived from artificially activated oocytes without embryo destruction, thus eliciting less ethic concerns, and have been demonstrated promising for autologous stem cell therapy. However, pES cells could carry inappropriate imprinting such as relatively high expression of H19, a paternal imprinted gene, and may negatively influence their lineage differentiation. We show that knockdown of H19 by shRNA in mouse pES cells does not alter self-renewal and expression of genes associated with pluripotency. We find that down-regulation of H19 promotes differentiation of pES cells to epidermis. In addition, H19 depletion also facilitates differentiation of pES cells to cardiomyocytes and strong heart-like beating. Our data support the notion that reduction of H19 improves pES cell differentiation in the lineages of ectoderm and mesoderm, and provide further evidence suggesting that defective imprinting can be manipulated to allow potential application of pES cells for stem cell therapy.
Export Options
About this article
Cite this article as:
Yin Y., Wang H., Liu K., Wang F., Ye X., Liu M., Xiang R., Liu N. and Liu L., Knockdown of H19 Enhances Differentiation Capacity to Epidermis of Parthenogenetic Embryonic Stem Cells, Current Molecular Medicine 2014; 14 (6) . https://dx.doi.org/10.2174/1566524014666140724101035
DOI https://dx.doi.org/10.2174/1566524014666140724101035 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Update on AKI Biomarker Patents
Current Biomarkers (Discontinued) Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Tipping the Balance Between Life and Death: Targeting Histone Acetylation for Cancer Therapy
Drug Delivery Letters Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic Approach to Cerebral Ischemia
Mini-Reviews in Medicinal Chemistry Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions
Current Topics in Medicinal Chemistry Diuretic-Associated Electrolyte Disorders in the Elderly: Risk Factors, Impact, Management and Prevention
Current Drug Safety Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets